News for Euronext N.V. (EUXTF)

**media[557580]**

**media[557579]**

**media[545218]**

**media[542017]**

Euronext Q4 results reveal 16.7% EBITDA growth and strategic innovations in European markets. Attractive valuation at a P/E of 15.3x makes it a strong buy.

Full-Year Revenue Growth: 10.3% increase to EUR1,626.9 million.Adjusted EBITDA: Exceeded EUR1 billion, with a 16.4% growth compared to 2023.Adjusted EBITDA Mar

Euronext N.V. (OTCPK:EUXTF) Q4 2024 Earnings Conference Call February 14, 2025 3:00 AM ETCompany ParticipantsStéphane Boujnah - Chairman & Chief...

The following slide deck was published by Euronext N.V.

**media[536936]**

**media[531059]**

Cboe Clear Europe has released an overview of its 2024 performance, highlighting growth across cash equities, new venue connections, and increased derivatives clearing volumes. The clearing house has also detailed its 2025 strategy, which includes the launch of Securities Financing Transaction (SFT) clearing and expanded post-trade services.

**media[525764]**

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

The RealPongCoin or $PONG is using Atari’s registered trademark without Atari’s consent or approval and the company has no affiliation with the crypto project

Atari Warns the Public that the RealPongCoin is Not Affiliated with Atari

PR NewswireLAKE LOUISE, AB, Jan. 21, 2025 Consciously Designed and Contemporary, Indoor-Outdoor, Lakeside Thermal Bathing Facility to Revolutionize Wellnes

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Vivendi's new 'galaxy' of companies needs more time to explain strategy, analysts and investors say

J.P. Morgan coordinates Bapco Energies Sukuk offering